Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(20 sites)
United States
Moores Cancer Center UC San Diego Health, La Jolla, California Keck School of Medicine of USC, Los Angeles, California UCLA, Los Angeles, California University of California, Davis Comprehensive Cancer Center, Sacramento, California H. Lee Moffitt Cancer Center and Research Institute, Inc, Tampa, Florida Dana Farber/Partners Cancer Care Inc, Boston, Massachusetts Memorial Sloan Kettering, New York, New York Columbia University Herbert Irving Comprehensive Cancer Center, New York, New York Levine Cancer Institute, Charlotte, North Carolina Cleveland Clinic, Cleveland, Ohio UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania Rhode Island Hospital, Providence, Rhode Island Medical University of South Carolina, Hollings Cancer Center, Charleston, South Carolina Vanderbilt University Medical Center, Nashville, Tennessee MD Anderson Cancer Center, Houston, Texas Australia
Chris O'Brien Lifehouse, Camperdown, New South Wales Calvary Mater Newcastle, Waratah, New South Wales Austin Hospital, Heidelberg, Victoria Peter MacCallum Cancer Centre, Melbourne, Victoria Canada
Princess Margaret Cancer Centre, Toronto, Ontario